Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMOAZHY)

Drug Name	Nemvaleukin alfa DMOAZHY
Drug Type	Fusion protein

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ovarian cancer	DISZJHAP	2C73	Phase 3	[1]
------------------------------------------------------------------------------------

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Cutaneous melanoma	DIS3MMH9	2C30	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05092360) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04830124) A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6. U.S.National Institutes of Health.